VEGFA and colorectal carcinoma: It is an open-label, single-arm study conducted on patients with MSS metastatic CRC, aiming to assess the efficacy and safety of a new drug combination as third-line or above therapy: FMT plus tislelizumab plus fruquitinib, a tyrosine kinase inhibitor of VEGF.